Sanofi Deal History & Licensing Activity
Sanofi is a large pharma headquartered in France. Over the past three years, Sanofi has been involved in 56 licensing and acquisition transactions, with a primary focus on Other (15 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
16
Active Trials
50
Top Modality
Other
Focus Area
Oncology
Sanofi Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sanofi in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| NanoDisc platform | Evoq Therapeutics | Other | Preclinical | license | May 2026 |
| MRT5400 / MRT5401 | Translate Bio | mRNA | Phase 2 | collaboration | Apr 2026 |
| duvakitug | Teva | Antibodies | Phase 2 | collaboration | Apr 2026 |
Sanofi Pipeline Focus
Therapeutic areas and modalities where Sanofi is most active based on deal history and clinical trial data.
Therapeutic Areas
Sanofi Strategic Signals
Key indicators of Sanofi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Sanofi Clinical Pipeline
Sanofi has 50 active clinical trials across 6 development phases.
9
Unknown
6
Phase 4
2
Not Applicable
4
Phase 1
10
Phase 2
19
Phase 3
See How Your Asset Matches Sanofi's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
About Sanofi Licensing & Deal Activity
Sanofi is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 56 deals over the past three years, Sanofi ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi include Oncology (25 deals and trials), Immunology (16 deals and trials), Gastroenterology (10 deals and trials), and Infectious Disease (8 deals and trials). In terms of modality, Sanofi has shown particular interest in other, bispecific antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sanofi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.